Literature DB >> 10967000

Follow-up of sperm concentration and motility in patients with lymphoma.

R Tal1, A Botchan, R Hauser, L Yogev, G Paz, H Yavetz.   

Abstract

Lymphomas are a group of diseases, prevalent at reproductive age. Fertility is notoriously reduced among lymphoma patients. This study evaluates pre- and post-treatment semen concentration and motility, and factors associated with semen quality deterioration. We followed-up 33 patients with non-Hodgkin's lymphoma or with Hodgkin's disease during the years 1987-1997 who were referred for semen cryopreservation. Pretreatment semen analysis, and hormonal profile were recorded at diagnosis and at least 1 year after completion of the treatment, and compared. Medical records for disease type, disease stage and treatment protocols were related to long-term sperm outcome. Hormonal concentrations were not predictive of post-treatment sperm concentration. In patients with localized disease, initial sperm concentration and motility tended to be preserved, compared with patients with widespread disease (P: = 0. 016). In Hodgkin's disease patients, treatment with the adriamycin, bleomycin, vinblastine and dacarbazine (ABVD) protocol was superior to the mechloretamine, vincristine, procarbazine and prednisone with ABV protocol regarding germinal toxicity (P: = 0.0008). The post-treatment sperm outcome was better in patients treated with local irradiation than in those who did not undergo irradiation (P: = 0.0027). No predictive tools for post-treatment fertility were found and, therefore, every patient with a lymphoma should have his semen cryopreserved at diagnosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10967000     DOI: 10.1093/humrep/15.9.1985

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  11 in total

Review 1.  The Therapeutic Potential of Mesenchymal Stromal Cells in the Treatment of Chemotherapy-Induced Tissue Damage.

Authors:  Alexander Rühle; Ramon Lopez Perez; Bingwen Zou; Anca-Ligia Grosu; Peter E Huber; Nils H Nicolay
Journal:  Stem Cell Rev Rep       Date:  2019-06       Impact factor: 5.739

2.  Reproductive patterns and non-Hodgkin lymphoma risk in Danish women and men.

Authors:  Morten Frisch; Bo V Pedersen; Jan Wohlfahrt; Henrik Hjalgrim; Robert J Biggar
Journal:  Eur J Epidemiol       Date:  2006-10-18       Impact factor: 8.082

Review 3.  Anticancer chemotherapeutic agents and testicular dysfunction.

Authors:  Kohei Yamaguchi; Masato Fujisawa
Journal:  Reprod Med Biol       Date:  2011-03-17

Review 4.  Fertility preservation in men with cancer.

Authors:  Koji Chiba; Masato Fujisawa
Journal:  Reprod Med Biol       Date:  2014-04-26

5.  Sperm banking and the cancer patient.

Authors:  Daniel H Williams
Journal:  Ther Adv Urol       Date:  2010-02

6.  Preservation of sperm of cancer patients: extent of use and pregnancy outcome in a tertiary infertility center.

Authors:  Amnon Botchan; Shiri Karpol; Ofer Lehavi; Gedalia Paz; Sandra E Kleiman; Leah Yogev; Haim Yavetz; Ron Hauser
Journal:  Asian J Androl       Date:  2013-03-25       Impact factor: 3.285

Review 7.  Fertility preservation in the male with cancer.

Authors:  Daniel H Williams
Journal:  Curr Urol Rep       Date:  2013-08       Impact factor: 3.092

8.  Recommendations for fertility preservation in patients with lymphomas.

Authors:  Kirsten Tryde Schmidt; Claus Yding Andersen
Journal:  J Assist Reprod Genet       Date:  2012-05-06       Impact factor: 3.412

9.  ABVD and BEACOPP regimens' effects on fertility in young males with Hodgkin lymphoma.

Authors:  M S A Amin; O Brunckhorst; C Scott; D Wrench; M Gleeson; M Kazmi; K Ahmed
Journal:  Clin Transl Oncol       Date:  2020-09-17       Impact factor: 3.405

10.  Breast cancer grade and stage do not affect fertility preservation outcomes.

Authors:  Kaitlyn Wald; Ange Wang; Mary Kathryn Abel; Jerrine Morris; Joseph M Letourneau; Evelyn Mok-Lin; Marcelle I Cedars; Mitchell P Rosen
Journal:  J Assist Reprod Genet       Date:  2022-03-23       Impact factor: 3.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.